Navigation Links
Covance Inc. Invites You to Join the Webcast of Its Second Quarter 2008 Financial Results Conference Call
Date:7/1/2008

PRINCETON, N.J., July 1 /PRNewswire-FirstCall/ -- In conjunction with its second quarter 2008 earnings release (expected to be issued after market close on July 30), Covance Inc. (NYSE: CVD) is pleased to invite you to listen to its quarterly investor conference call that will be broadcast live over the Internet on Thursday, July 31, 2008 at 9:00 a.m. ET.

What: Covance Second Quarter 2008 Earnings Webcast and Slide

Presentation

When: July 31, 2008, 9:00 a.m. ET*

Where: http://www.covance.com

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.5 billion, global operations in more than 20 countries, and more than 8,900 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at http://www.covance.com.

*If you are unable to participate during the live webcast, the event will be archived on the web site http://www.covance.com for 14 days.


'/>"/>
SOURCE Covance Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Covance to Present at the William Blair Growth Stock Conference
2. Covance Elects Joseph C. Scodari to Companys Board of Directors
3. Covance Inc. Invites You to Join the Webcast of Its First Quarter 2008 Financial Results Conference Call
4. Covance to Present at Lehman Brothers 11th Annual Global Healthcare Conference
5. Covance to Present at Raymond James 29th Annual Institutional Investors Conference
6. Covance to Present at UBS Global Healthcare Services Conference
7. Covance to Present at 26th Annual JPMorgan Healthcare Conference
8. Wendel Barr Appointed Chief Operating Officer of Covance
9. Covance and Care Partner on Rwanda Early Childhood Development Initiative
10. eResearchTechnology, Inc. to Announce Agreement to Acquire the Centralized ECG Business of Covance
11. eResearchTechnology (eRT) Agrees to Acquire the Centralized ECG Business of Covance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... This report studies the global ... forecast period of 2014 to 2019. This market ... 6.5% from 2014 to 2019. , Further Inquiry ... the global pharmacovigilance and drug safety software market ... basis of functionality, namely, adverse event reporting software, ...
(Date:3/30/2015)... On March 19th, 2015, in the ... the Detroit Lions, LiveToBeSober.org hosted the “Fighting Addiction Together” ... and bishops as well as other civic leaders and ... the luncheon, including retired Detroit Lions wide receiver Herman ... two survivors of their own personal battles with addiction, ...
(Date:3/30/2015)... Dr. Shahdad Arami is now ... receive $200 off their Invisalign treatment. Many people crave ... a mouthful of metal. Invisalign offers an alternative. According ... is effective for straightening teeth but has no aesthetic ... oral appearance. The Invisalign system allows both teenagers and ...
(Date:3/30/2015)... FMC Corporation’s Health and Nutrition ... current Epax® Ultra and Core concentrates manufactured in ... certification ensures the manufacturing process and all physical ... regulations for Halal. , The new Halal ... further advance its customer service to a global ...
(Date:3/30/2015)... Los Angeles, CA (PRWEB) March 30, 2015 ... its traditional blue polo for yellow to inspire courage ... who suffers from Severe Combined Immunodeficiency (SCID). SCID causes ... a bone marrow transplant is needed to allow the ... his second transplant last Friday, created a video with ...
Breaking Medicine News(10 mins):Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 2Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 3Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 4Health News:LiveToBeSober.org Releases Highlight Reel of Substance Abuse Conference Keynote Speakers 2Health News:Northridge Cosmetic Dentist, Dr. Arami, is Now Offering a New Promotion on Invisalign 2Health News:FMC Health and Nutrition Announces Halal Certification for Epax® Brand Omega-3 Ingredients 2Health News:24Hr HomeCare Staff Hosts #WearYellowForSeth Campaign for Five-Year-Old Boy with Severe Combined Immunodeficiency 2
... HRAL) announced that it has received additional licenses from,Wal-Mart ... WMT ), to open their ninth and tenth ... #3195 located at 1070 Major,Mackenzie Drive in Richmond Hill ... Y006A in Markham will both officially open today. This,expansion ...
... ... 2008 Guidance Amedisys to Host ... Amedisys, Inc.,(Nasdaq: AMED ) ("Amedisys" or "the Company"), one of America,s ... September 30, 2007: Three-Month Periods Ended September 30, 2007 and 2006, ...
... Pieris AG,(Munich, Germany) and Pepscan ... of a research collaboration aimed at ... (GPCRs) and their,development as therapeutic candidates. ... next generation targeted,therapeutics with clear advantages ...
... Oct. 30 CryoLife, Inc. (NYSE: CRY ),a ... Scott B. Capps has been named vice president, clinical ... vice president and,general manager of CryoLife Europa, Ltd., based ... CryoLife in 1995 and has held several positions with,the ...
... at launch, due to its First To File ... ... owned subsidiary of Ranbaxy Laboratories Limited (RLL),announced today that RLL has received tentative ... 40 mg,80 mg, 160 mg and 320 mg. Total annual market sales for ...
... to Mouth Guards, GLENDALE, Calif., Oct. 23 ... to pay as much attention to,you oral health as ... concerned about their total health, weight issues and,being healthy, ... health of,their mouth," said Jean Honny, president of the ...
Cached Medicine News:Health News:HearAtLast Continues Rapid Expansion, Opening Two New Retail Locations in Richmond Hill and Markham Wal-Mart Stores Number 3195 and 3053 2Health News:HearAtLast Continues Rapid Expansion, Opening Two New Retail Locations in Richmond Hill and Markham Wal-Mart Stores Number 3195 and 3053 3Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 2Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 3Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 4Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 5Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 6Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 7Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 8Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 9Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 10Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 11Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 12Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 13Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 14Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 15Health News:Pieris and Pepscan to Identify GPCR-Specific Anticalins(R) Using CLIPS(TM) Protein Mimicry Technology 2Health News:Pieris and Pepscan to Identify GPCR-Specific Anticalins(R) Using CLIPS(TM) Protein Mimicry Technology 3Health News:CryoLife Announces Additions to Management Team 2Health News:Ranbaxy Receives Tentative Approval For Valsartan Tablets 2Health News:California Dental Hygienists Offer Health Tips for Weekend Warriors & Fitness Buffs 2
(Date:3/30/2015)... , March 30, 2015  BioDelivery Sciences ... the primary efficacy endpoint in the Phase 3 ... placebo for the treatment of painful diabetic neuropathy ... endpoints showed statistically significant improvement over placebo.  In ... was observed.  The results of this trial provide ...
(Date:3/29/2015)... TITUSVILLE, N.J. , March 29, 2015 /PRNewswire/ ... delayed time to relapse compared to placebo in ... 3 clinical study published this week in the ... (JAMA) Psychiatry . Results of ... recent New Drug Application (NDA) filing for three-month ...
(Date:3/27/2015)... /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") ... the issuance of an aggregate of 30,000 stock options ... aggregate of 120,500 stock options to employees and consultants ... three years and will be exercisable for a period ... per stock option. About Covalon Covalon ...
Breaking Medicine Technology:BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 2BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 3BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 4BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 5New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 2New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 3New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 4New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 5New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 6New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 7New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 8New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 9New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 10New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 11New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 12Covalon Announces Issuance of Stock Options 2
... , PRINCETON, N.J. and SAN DIEGO, ... biotechnology company committed to research and product discovery for ... announced results from an in vitro study evaluating TBR-652 ... tenofovir (TDF), etravirine (ETV), and raltegravir (RAL) using the ...
... PARIS and TARRYTOWN, N.Y., Sept. 11 Sanofi-aventis ... Pharmaceuticals, Inc. (Nasdaq: REGN ) today announced the ... Trap) plus gemcitabine versus placebo plus gemcitabine for the first-line ... by an Independent Data Monitoring Committee (IDMC). As part ...
Cached Medicine Technology:Tobira Therapeutics Inc. Announces In Vitro Data of TBR-652 for the Treatment of HIV 2Phase 3 Trial of Aflibercept in Metastatic Pancreatic Cancer Discontinued 2Phase 3 Trial of Aflibercept in Metastatic Pancreatic Cancer Discontinued 3Phase 3 Trial of Aflibercept in Metastatic Pancreatic Cancer Discontinued 4Phase 3 Trial of Aflibercept in Metastatic Pancreatic Cancer Discontinued 5
Implex cemented hip stem....
Stability cemented stem....
Porous foundation 440 series....
Exactech's AcuMatch C-Series (cemented femoral stem) is designed to provide solutions to the problems which compromise both the short and long term successful outcome of cemented hip arthroplasty....
Medicine Products: